Inclusion Criteria:

          -  Genetic diagnosis of classical familial adenomatous polyposis (FAP) (adenomatous
             polyposis coli [APC] germline mutation or obligate carrier) with disease involvement
             of the colorectum

          -  At least 6 polyps greater than or equal to (>=) 2 millimeters (mm) in diameter in the
             rectum or colon

          -  A female participant of childbearing potential must have a negative highly sensitive
             pregnancy test at screening and within 72 hours prior to the first dose of study drug
             and must agree to further pregnancy tests during the study

          -  A male participant must agree not to donate sperm for the purpose of reproduction
             during the study and for a minimum of 90 days after receiving the last dose of study
             drug

          -  Must sign an informed consent form (ICF) indicating he or she understands the purpose
             of the study and procedures required for the study and is willing to participate in
             the study. Consent is to be obtained prior to the initiation of any study-related
             tests or procedures that are not part of standard of care for the participant's
             disease

        Exclusion Criteria:

          -  Use of non-steroidal anti-inflammatory drugs (example, aspirin, ibuprofen) exceeding 5
             days per month, unless completes a 4-week washout period prior to the first dose of
             study drug

          -  Treatment with other FAP-directed drug therapy (including sulindac or celecoxib),
             unless completes a 4-week washout period prior to the first dose of study drug

          -  History of human immunodeficiency virus (HIV)

          -  History of severe, progressive, or uncontrolled renal, genitourinary, hepatic,
             hematologic, endocrine, cardiac, vascular (including increased risk of thrombosis),
             pulmonary, rheumatologic, neurologic, psychiatric, or metabolic disturbances, or signs
             and symptoms thereof

          -  A history of, or ongoing, chronic or recurrent infectious disease including latent or
             active tuberculosis (TB)